Study Finds Cannabis Use Linked to Nearly Fourfold Rise in Type 2 Diabetes Risk
A large TriNetX analysis of electronic health records from over 4 million U.S. adults found cannabis-related diagnoses were associated with nearly a fourfold higher risk of developing type 2 diabetes over five years, researchers reported at EASD 2025.
- Large real-world sample: Analysis used records from 54 health organizations and >4 million adults via the ScienceDaily-reported TriNetX dataset.
- Risk contrast: New diabetes developed in 2.2% of 96,795 adults with cannabis-related diagnoses vs. 0.6% of matched non-users over five years (Medical Xpress).
- Adjusted association: After controlling for metabolic and lifestyle factors, cannabis users had nearly a fourfold higher risk of type 2 diabetes (ScienceDaily).
What the study did and found
Data and cohort: Investigators pulled electronic health records from 54 U.S. health centers (2010–2018) using the TriNetX Research Network. They identified 96,795 adults ages 18–50 with cannabis-related diagnoses (ranging from occasional use to dependence) and matched them by age, sex and comorbidities to >4.16 million adults without substance-use records or major chronic diseases.
Follow-up and adjustments: Participants were followed for five years. Analyses adjusted for cholesterol, hypertension, cardiovascular disease and other substance use (including alcohol and cocaine), among other metabolic and lifestyle risks (ScienceDaily).
Key outcomes: New diabetes diagnoses occurred in 1,937 people in the cannabis group (2.2%) and in 518 people in the non-user group (0.6%). After statistical adjustment, cannabis-associated diagnoses correlated with nearly a fourfold higher risk of developing type 2 diabetes; the finding was presented at the 2025 Annual Meeting of the European Association for the Study of Diabetes (EASD) (Medical Xpress; ScienceDaily).
Possible explanations and study limitations
Experts propose several plausible mechanisms including increased insulin resistance and diet-related pathways: short-term appetite stimulation (“the munchies”), consumption of high-sugar or high-fat cannabis products, and product-specific chemical profiles (THC, CBD, other compounds) that may differently affect glucose metabolism (Medical Xpress).
Limitations: The dataset relies on diagnostic coding and likely underreports cannabis use unless clinically recorded. It lacks granular lifestyle data—diet, exercise, socioeconomic status—and precise measures of dose, frequency or route (smoked, vaped, edible), which could confound the association (ScienceDaily).
How this fits with past research
Prior studies have produced mixed results. Some analyses reported no clear link after adjusting for age and other factors. The new TriNetX analysis differs by scale, follow-up length and method—factors that may explain a stronger observed association. Experts stress the need for more large, well-designed prospective studies that capture detailed patterns of use and metabolic markers over time (PubMed Central; PubMed).
Expert reaction and clinical advice
Clinical recommendations: Lead author Dr. Ibrahim Kamel and colleagues urge clinicians to ask about cannabis use, consider routine diabetes screening and metabolic monitoring for users, and counsel on lifestyle measures—diet, activity, weight management—to mitigate risk (ScienceDaily; Medical News Today).
Quote from experts:
“Clinicians should ask patients about cannabis use and consider earlier or more frequent metabolic screening for users, especially those with other risk factors,” the investigators recommend (ScienceDaily).
Public health context and San Diego implications
With rising cannabis use in the U.S. and parts of Europe, a confirmed link to type 2 diabetes could have substantial public-health impact. Policymakers, clinicians and public-health officials should consider this emerging evidence when crafting prevention messages and screening recommendations (Medical News Today; Economic Times).
San Diego-specific considerations:
- Economic: Local cannabis businesses and dispensaries may face scrutiny; product labeling and health warnings could be emphasized.
- Political: City and county leaders might update guidance on sales, prevention programs and funding for screening initiatives.
- Social: Communities with higher cannabis use—young adults and some lower-income neighborhoods—could see disproportionate effects; outreach should be nonjudgmental and accessible.
- Practical: Clinicians should integrate cannabis-use questions into electronic health records and consider earlier glucose monitoring; residents can reduce risk by improving diet, activity and regular checkups.
Where researchers want to go next and where to read more
Investigators call for prospective studies with repeated lab tests (glucose, insulin), distinctions by product type/route/dose, subgroup analyses (age, sex, race/ethnicity, pre-existing metabolic conditions) and mechanistic laboratory/clinical work to test how cannabis compounds affect insulin resistance and pancreatic function (ScienceDaily; Medical Xpress).
Further reading and coverage:
- ScienceDaily — full study summary and press coverage
- Medical Xpress — additional reporting
- Medical News Today — analysis and expert commentary
- Economic Times — international reporting
- PubMed Central — contrasting studies and PubMed entry
- Diatribe — lifestyle coverage and context
Bottom line: The new, large-scale real-world analysis signals a potentially important link between cannabis-related diagnoses and higher type 2 diabetes risk. While not definitive, the findings justify clinician screening, patient counseling and further research to clarify causation and mechanisms.
